Fennec Pharmaceuticals INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Marco Maria Brughera, a Director of Fennec Pharmaceuticals Inc., sold 15,545 shares of common stock on September 15, 2026 for $10.29 per share.
NASDAQ
Rosty Raykov, Former Director of Fennec Pharmaceuticals Inc., sold 10,000 shares of common stock on August 31, 2026 for $12.11 per share.
NASDAQ
Pierre Sargis Sayad, Chief Medical Officer of Fennec Pharmaceuticals Inc., sold 12,000 shares of common stock on August 31, 2026 for $12.18 per share.
NASDAQ
Terry L Evans, Chief Commercial Officer of Fennec Pharmaceuticals Inc., received 168 shares of common stock on August 31, 2026.
NASDAQ
Christiana Marie Cioffi, Chief Strategy Officer of Fennec Pharmaceuticals Inc., received 156 shares of common stock on August 31, 2026.
NASDAQ
Jeffrey S. Hackman, Chief Executive Officer and a Director of Fennec Pharmaceuticals Inc., received 1,159 shares of common stock on August 31, 2026.
NASDAQ
Robert Andrade, CHIEF FINANCIAL OFFICER of Fennec Pharmaceuticals Inc., received 1,703 shares of common stock on August 31, 2026.
NASDAQ
Robert Andrade, CHIEF FINANCIAL OFFICER of Fennec Pharmaceuticals Inc., sold 75,000 shares of common stock on August 27, 2026 for $11.78 per share.
NASDAQ
Pierre Sargis Sayad, Chief Medical Officer of Fennec Pharmaceuticals Inc., received 168 shares of common stock on July 31, 2026.
NASDAQ
Terry L Evans, Chief Commercial Officer of Fennec Pharmaceuticals Inc., received 168 shares of common stock on July 31, 2026.
NASDAQ
Christiana Marie Cioffi, Chief Strategy Officer of Fennec Pharmaceuticals Inc., received 156 shares of common stock on July 31, 2026.
NASDAQ
Jeffrey S. Hackman, Chief Executive Officer and a Director of Fennec Pharmaceuticals Inc., received 1,159 shares of common stock on July 31, 2026.
NASDAQ
Terry L. Evans, Chief Commercial Officer of Fennec Pharmaceuticals, reported a transaction involving the release of restricted shares.
NASDAQ
Pierre Sargis, Chief Medical Officer at Fennec Pharmaceuticals, acquired 168 common shares on June 30, 2026, as shares were released from restriction.
NASDAQ
Fennec Pharmaceuticals CEO Jeffrey S. Hackman reported a transaction involving 1,159 common shares on June 30, 2026.
NASDAQ
Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, acquired 1,703 common shares on June 30, 2026, increasing his direct beneficial ownership.
NASDAQ
Christiana Cioffi, Chief Strategy Officer at Fennec Pharmaceuticals, reported a transaction involving common shares.
NASDAQ
Director Marco Brughera was granted 20,000 stock options in Fennec Pharmaceuticals on June 10, 2026.
NASDAQ
Director Jodi A. Cook was granted 20,000 stock options in Fennec Pharmaceuticals Inc. on June 10, 2026.
NASDAQ
Director Khalid Islam was granted 25,000 stock options in Fennec Pharmaceuticals, Inc. as part of the company's equity incentive plan.
NASDAQ
Director Chris Rallis was granted 20,000 stock options in Fennec Pharmaceuticals as part of the company's equity incentive plan.
NASDAQ
Terry L. Evans, Chief Commercial Officer of Fennec Pharmaceuticals, reported a transaction involving the release of restricted shares.
NASDAQ
Pierre Sargis, Chief Medical Officer of Fennec Pharmaceuticals, reported the acquisition of 168 common shares on May 31, 2026.
NASDAQ
Jeffrey S. Hackman, CEO and Director of Fennec Pharmaceuticals, reported a transaction involving common shares.
NASDAQ
Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, acquired 1,703 common shares on May 31, 2026, increasing his direct beneficial ownership.
NASDAQ
Fennec Pharmaceuticals Director Chris Rallis executed a 10b5-1 plan, acquiring shares via option exercise and selling shares to cover taxes.
NASDAQ
Fennec Pharmaceuticals Director Rosty Raykov exercised stock options and sold shares to cover tax obligations under a 10b5-1 plan.
NASDAQ
Chief Commercial Officer Terry L. Evans acquired 168 common shares of Fennec Pharmaceuticals through the release of restricted stock.
NASDAQ
Chief Strategy Officer Christiana Marie Cioffi acquired 155 common shares of Fennec Pharmaceuticals through the vesting of restricted stock units.
NASDAQ
CEO Jeffrey Hackman acquired 1,159 common shares of Fennec Pharmaceuticals through the release of restricted stock units.